Xoma reported 52.12 in PE Price to Earnings for its fiscal quarter ending in September of 2022.





Pe Change Date
AbbVie 24.03 86.23 Dec/2025
Agios Pharmaceuticals 3.56 0.68 Sep/2025
BioMarin Pharmaceutical 19.24 0.21 Dec/2025
Eli Lilly 40.21 9.66 Dec/2025
Emergent BioSolutions 14.4 2.25 Sep/2022
Incyte 14.84 2.79 Dec/2025
Novartis 17.85 2.11 Dec/2025
Novartis 17.79 1.74 Dec/2025
Pfizer 14.48 5.18 Dec/2025
Prothena 22.11 11.37 Mar/2022
Regeneron Pharmaceuticals 18.11 2.91 Dec/2025
Xoma 52.12 3.09 Sep/2022